Article: EPB41L4A-AS1 and Nicotinamide Riboside Support Brain Energy and Slow Aging: Preclinical FIndings

PrevNext
Alzheimer's Disease Healthy Aging & Longevity Neurological Health Preclinical

EPB41L4A-AS1 and Nicotinamide Riboside Support Brain Energy and Slow Aging: Preclinical FIndings

Synopsis

The long non-coding RNA EPB41L4A-AS1 helps regulate NAD+ and ATP production in the brain, which are critical for energy and cellular function. In aging and Alzheimer's disease, EPB41L4A-AS1 levels drop, leading to reduced NAD+ and ATP, which may accelerate brain aging and neurodegeneration. Experiments showed that boosting EPB41L4A-AS1 or treating cells with nicotinamide riboside (NR), a precursor for NAD+, restored NAD+ and ATP levels, suggesting that supporting this pathway can help maintain brain energy and potentially slow neurodegenerative processes.

Journal

Cell & Bioscience

Share

Read more

Alzheimer's Disease

Mitophagy Enhancers, Including Nicotinamide Riboside, Protect Neurons from Tau-Induced Damage in Alzheimer’s Disease: Preclinical Findings

Synopsis In Alzheimer’s disease (AD), abnormal tau proteins damage mitochondria and synapses, leading to impaired energy production and neuron loss. In mouse hippocampal neurons expressing mutant ...

Read more
Amyotrophic Lateral Sclerosis (ALS)

Rare SARM1 Variants Linked to ALS and Motor Nerve Disorders: Preclinical Findings

SynopsisSARM1 is a protein that breaks down NAD+, playing a key role in axon degeneration. Researchers found seven rare SARM1 gene variants in patients with ALS or other motor nerve disorders. Thes...

Read more